SNHG6 and breast carcinoma: Silencing SNHG6 sensitizes resistant cells to tamoxifen, reverses EMT, and reduces invasion and clonogenicity, implicating the SNHG6-miR-101 axis as a potential target for overcoming tamoxifen resistance in breast cancer.